Consun Pharmaceutical Group Ltd. (1681) AI Stock Analysis

• Market Cap: HK$14.61B
• Dividend Yield: 3.93%
• Average Volume (3M): 2.00M
• Price to Earnings (P/E): 13.8
• Beta (1Y): 0.54
• Revenue Growth: 19.05%
• EPS Growth: 13.68%
• Country: HK
• Employees: 3,164
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.65
• Shares Outstanding: 841,241,940
• 10 Day Avg. Volume: 1,421,042
• 30 Day Avg. Volume: 1,998,301
• PEG Ratio: 0.52
• Price to Book (P/B): 1.53
• Price to Sales (P/S): 2.12
• P/FCF Ratio: 6.43
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 72 Outperform
• Price Target: HK$19.50 ▲(26.38% Upside)

Consun Pharmaceutical Group Ltd. exhibits strong financial performance with robust revenue growth and profitability. The stock's valuation is attractive with a reasonable P/E ratio and a solid dividend yield. However, technical indicators suggest weak momentum, which could pose short-term challenges.

Positive Factors

Revenue Growth Trend

Nearly 19% reported revenue growth indicates sustained top-line expansion over recent periods. Durable revenue momentum supports reinvestment in R&D and capacity, helps capture market share in TCM and modern pharma, and underpins long-term product portfolio scaling if execution continues.

High and Improving Profitability

Exceptionally high gross margins and a substantial rise in net margin reflect strong product mix, pricing power, and operating leverage. These durable margin characteristics support robust internal cash generation, fund R&D and capex, and provide a structural buffer against cost inflation over the medium term.

Stronger Balance Sheet / Lower Leverage

Improving debt-to-equity and a strong equity base increase financial flexibility and resilience. Reduced leverage lowers refinancing and interest-rate risk, enabling strategic investments, M&A or shareholder returns, and better cushions the company against industry cyclicality or regulatory shifts over time.

Negative Factors

Sustainability of High Growth

While historical growth has been strong, maintaining very high rates becomes harder as scale grows. Competitive pressures, product lifecycle limits and regulatory complexity in pharma can compress future growth; normalization would pressure expectations for reinvestment and margin expansion.

Underutilized Cash Reserves

Elevated cash balances point to conservative capital deployment and potential opportunity cost. If excess cash is not channeled into high-return capex, M&A, or more efficient capital returns, long-term ROE and shareholder value could lag peers despite strong underlying profitability.

Limited Recent Cash Flow Transparency

Absence of up-to-date cash flow figures constrains confidence in the sustainability of free cash generation. This opacity makes it harder to judge funding capacity for capex, R&D, dividends or debt servicing, raising execution and liquidity assessment risk over the coming months.

Consun Pharmaceutical Group Ltd. Business Overview & Revenue Model

Company Description

Consun Pharmaceutical Group Ltd. (1681) is a leading pharmaceutical company based in China, specializing in the research, development, production, and distribution of a diverse range of pharmaceutical products. The company primarily focuses on traditional Chinese medicine, modern pharmaceuticals, and healthcare products, catering to both domestic and international markets. With a commitment to innovation and quality, Consun aims to enhance health outcomes through its extensive portfolio of medicines and wellness solutions.

How the Company Makes Money

Consun Pharmaceutical Group Ltd. generates revenue through multiple streams, primarily from the sale of its pharmaceutical products, which include both traditional Chinese medicines and modern pharmaceuticals. The company leverages its robust research and development capabilities to create innovative products that meet the evolving needs of patients. Additionally, Consun benefits from strategic partnerships with healthcare institutions and distributors, enhancing its market reach and distribution efficiency. The company also explores opportunities in export markets, contributing to its revenue growth. Furthermore, ongoing investments in production facilities and technology help to optimize costs and improve margins, ultimately driving profitability.

Consun Pharmaceutical Group Ltd. Financial Statement Overview

Summary

Consun Pharmaceutical Group Ltd. demonstrates strong financial health with robust revenue growth and profitability margins. The balance sheet is stable with decreasing leverage and increasing equity. However, limited recent cash flow data restricts a full assessment of cash generation efficiency.

Income Statement

Consun Pharmaceutical Group Ltd. has demonstrated strong growth in revenue, consistently increasing from 2019 to 2024. The company shows impressive profitability with a gross profit margin consistently above 75% and a net profit margin improving from 4.6% in 2019 to 30.7% in 2024. EBIT and EBITDA margins have also shown positive trends, indicating effective cost management. However, the high growth rate may pose sustainability challenges in future periods.

Balance Sheet

The company maintains a robust balance sheet with a strong equity position and increasing total assets. The debt-to-equity ratio has improved, reflecting reduced leverage over the years. The return on equity has also improved significantly, indicating efficient use of equity capital. Nonetheless, high cash reserves might suggest underutilization of funds, which could be optimized for growth or shareholder returns.

Cash Flow

Consun Pharmaceutical Group Ltd. has maintained positive free cash flow consistently, although recent data is unavailable for comprehensive analysis. The company has shown the ability to generate cash from operations, but the lack of recent cash flow data limits a full assessment. Historical trends suggest sound cash flow management, but recent growth in free cash flow percentages are needed for a clearer picture.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.27B	2.97B	2.59B	2.34B	2.04B	1.75B
Gross Profit	2.50B	2.24B	1.92B	1.76B	1.53B	1.32B
EBITDA	1.14B	1.05B	963.06M	785.89M	728.71M	618.79M
Net Income	1.01B	910.46M	784.53M	682.91M	590.17M	498.79M
Balance Sheet
Total Assets	6.09B	5.85B	5.51B	4.89B	4.36B	3.95B
Cash, Cash Equivalents and Short-Term Investments	4.04B	3.87B	3.58B	3.04B	2.43B	1.94B
Total Debt	253.35M	267.17M	511.53M	460.18M	610.97M	549.41M
Total Liabilities	1.45B	1.46B	1.59B	1.45B	1.45B	1.43B
Stockholders Equity	4.35B	4.10B	3.63B	3.15B	2.62B	2.22B
Cash Flow
Free Cash Flow	1.14B	977.99M	766.41M	896.09M	627.29M	818.36M
Operating Cash Flow	1.23B	1.09B	818.97M	947.68M	725.54M	867.06M
Investing Cash Flow	-901.34M	-186.91M	-231.77M	-368.80M	-298.31M	-25.70M
Financing Cash Flow	-652.30M	-729.26M	-280.10M	-342.20M	-166.66M	-279.80M

Consun Pharmaceutical Group Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 15.43
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1681, the sentiment is Positive. The current price of 15.43 is below the 20-day moving average (MA) of 16.93, below the 50-day MA of 15.84, and above the 200-day MA of 13.57, indicating a bullish trend. The MACD of 0.62 indicates Negative momentum. The RSI at 70.12 is Negative, neither overbought nor oversold. The STOCH value of 68.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1681.

Consun Pharmaceutical Group Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2877	73 Outperform	HK$7.14B	8.00	10.85%	5.80%	-20.64%	-25.39%
1681	72 Outperform	HK$14.61B	13.77	25.92%	3.93%	19.05%	13.68%
0719	58 Neutral	HK$10.67B	11.95	7.48%	4.47%	1.65%	-16.38%
0570	54 Neutral	HK$10.52B	-36.80	-1.26%	3.66%	-9.58%	-128.83%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
0460	50 Neutral	HK$14.65B	-165.26	-1.87%	0.87%	19.21%	-115.91%

Consun Pharmaceutical Group Ltd. Corporate Events

Consun Pharma Expands Share Buyback to HKD300 Million Amid Confidence in Growth Outlook

Consun Pharmaceutical Group Limited has expanded its existing share repurchase initiative, authorising an additional HKD100 million in buybacks under its current mandate, bringing the total potential repurchase scale to up to HKD300 million, or no more than 10% of its issued share capital, to be executed in the open market up to the next annual general meeting. Management says the move reflects confidence in the company’s fundamentals and believes the stock is undervalued, aiming to optimise capital structure and enhance per-share metrics while funding the repurchases from existing cash resources, though the timing and volume of any actual buybacks will depend on market conditions and remain at the company’s discretion.

The most recent analyst rating on (HK:1681) stock is a Buy with a HK$20.50 price target. To see the full list of analyst forecasts on Consun Pharmaceutical Group Ltd. stock, see the HK:1681 Stock Forecast page.

Consun Pharmaceutical Tightens ESG Governance With Updated Committee Mandate

Consun Pharmaceutical Group Ltd. has formalised and updated the terms of reference for its Environmental, Social and Governance (ESG) Committee, effective 23 December 2025, to align with Hong Kong Listing Rules and strengthen oversight of ESG and climate-related issues. The Board-appointed committee, chaired by the board chairman and supported by the company secretary, will comprise at least two directors with ESG and climate expertise, meet at least annually, and is empowered to obtain information from employees, external parties and professional advisers at the company’s expense for ESG reporting and governance. By institutionalising these structures and powers, the company is reinforcing its ESG governance framework and signalling to regulators, investors and other stakeholders that it is enhancing its capacity to manage climate risks, comply with disclosure requirements and respond to rising market expectations on sustainability.

The most recent analyst rating on (HK:1681) stock is a Buy with a HK$17.00 price target. To see the full list of analyst forecasts on Consun Pharmaceutical Group Ltd. stock, see the HK:1681 Stock Forecast page.

Consun Pharmaceutical Shareholders Approve New Award Scheme and Amended Governance Documents at EGM

Consun Pharmaceutical Group Limited announced that all resolutions proposed at its extraordinary general meeting held on 23 December 2025 were duly approved by shareholders by way of poll, with all directors attending in person or via video conference. Shareholders passed the adoption of a new share award scheme and a sublimit for service providers, as well as amendments to and a full restatement of the company’s Memorandum and Articles of Association, signaling board and investor alignment on revised incentive structures and updated corporate governance arrangements.

The most recent analyst rating on (HK:1681) stock is a Buy with a HK$17.00 price target. To see the full list of analyst forecasts on Consun Pharmaceutical Group Ltd. stock, see the HK:1681 Stock Forecast page.

Consun Pharmaceutical Group to Discuss New Share Award Scheme and Amendments

Consun Pharmaceutical Group Limited has announced an extraordinary general meeting to discuss and potentially approve a new share award scheme. This scheme aims to issue up to 84,281,191 shares to eligible participants, including a sublimit of 8,428,119 shares for service providers. Additionally, the company plans to amend its memorandum and articles of association to better align with its strategic goals.

The most recent analyst rating on (HK:1681) stock is a Buy with a HK$17.00 price target. To see the full list of analyst forecasts on Consun Pharmaceutical Group Ltd. stock, see the HK:1681 Stock Forecast page.

Consun Pharmaceutical Schedules EGM for Share Scheme and Governance Amendments

Consun Pharmaceutical Group Ltd. has announced the scheduling of an Extraordinary General Meeting (EGM) on December 23, 2025, to discuss and approve the proposed adoption of a Share Award Scheme and amendments to its memorandum and articles of association. This move is aimed at holding treasury shares and adopting new governance documents, potentially impacting shareholder engagement and corporate governance practices.

The most recent analyst rating on (HK:1681) stock is a Buy with a HK$17.00 price target. To see the full list of analyst forecasts on Consun Pharmaceutical Group Ltd. stock, see the HK:1681 Stock Forecast page.

Consun Pharmaceutical Proposes New Share Award Scheme

Consun Pharmaceutical Group Ltd. has proposed the adoption of a Share Award Scheme to incentivize and reward participants for the growth and development of the company. This scheme, which requires shareholder approval, aims to grant new shares under the Listing Rules, enhancing the company’s ability to motivate its workforce. The announcement also notes the expiration of the 2013 Share Option Scheme and the introduction of the 2024 Share Option Scheme, which has not yet granted any options but has set limits for future share allocations.

The most recent analyst rating on (HK:1681) stock is a Buy with a HK$17.00 price target. To see the full list of analyst forecasts on Consun Pharmaceutical Group Ltd. stock, see the HK:1681 Stock Forecast page.

Consun Pharmaceutical Proposes Amendments to Memorandum for Treasury Shares

Consun Pharmaceutical Group Limited, a company incorporated in the Cayman Islands, has announced proposed amendments to its existing memorandum and articles of association. These amendments aim to allow the company to hold and dispose of repurchased shares as treasury shares, in line with Cayman Islands law and recent changes to the Hong Kong Stock Exchange’s listing rules. The changes are pending shareholder approval at an upcoming extraordinary general meeting.

The most recent analyst rating on (HK:1681) stock is a Buy with a HK$17.00 price target. To see the full list of analyst forecasts on Consun Pharmaceutical Group Ltd. stock, see the HK:1681 Stock Forecast page.